Heron Therapeutics (HRTX) Management Meeting Increases Confidence in Label Expansion and Reimbursement - Jefferies
Tweet Send to a Friend
Jefferies analyst Kelly Shi reiterated a Buy rating and $23.00 price target on Heron Therapeutics (NASDAQ: HRTX) after meeting with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
